Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04220970
Recruiting Observational

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

NCT04220970 · tracked via the Priya Life Science France tracker
Sponsor
The Lymphoma Academic Research Organisation
Phase
Observational
Started
2017-06-07
Last updated
2026-01-14

Condition(s) studied

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)

Investigational drug(s) / intervention(s)

BIA-ALCL

BIA-ALCL: Observational : no intervention

Study summary

Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant.

Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP).

This registry is opened in France and in Belgium

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients with an anaplastic large cell lymphoma associated with breast implants Exclusion Criteria: \-

Primary outcome measure(s)

  • Overall response — 13 years

Trial sites (31)

FacilityCityRegionStatus
A. Z. Sint-Jan Brugge-Oostende AV Bruges Belgium Recruiting
Clinique Universitaire Saint LUC Brussels Belgium Recruiting
Cliniques Universitaires de Bruxelles - Hôpital Erasme Brussels Belgium Not Yet Recruiting
Institut Jules Bordet Brussels Belgium Recruiting
Universitair Ziekenhuis Brussel Brussels Belgium Not Yet Recruiting
Universitair Ziekenhuis Antwerpen Edegem Belgium Not Yet Recruiting
Universitair Ziekenhuis Gent Ghent Belgium Recruiting
U.Z. Leuven - Campus Gasthuisberg Leuven Belgium Recruiting
CHU de Liège -Domaine Sart Tilman Liège Belgium Recruiting
CHU UCL Namur - Site Godinne Yvoir Belgium Recruiting
CH d Avignon - Hopital Henri Duffaut Avignon France Recruiting
Institut Bergonié Bordeaux France Recruiting
CHRU de Brest - Hôpital Morvan Brest France Recruiting
Hopital Louis Pasteur Colmar France Recruiting
APHP - Hopital Henri Mondor Créteil France Recruiting
CHU de Dijon - Hôpital le Bocage Dijon France Recruiting
Centre Médical la Roseraie Lille France Recruiting
Centre Léon Bérard Lyon France Recruiting
Institut Paoli Calmettes Marseille France Recruiting
CH Saint-Eloi Montpellier France Recruiting
CHU de Nantes - Hôtel Dieu Nantes France Recruiting
Hôpital Cochin Paris France Recruiting
CH de Pau Pau France Recruiting
CH de Perpigan Perpignan France Recruiting
Centre Hospitalier Lyon Sud Pierre-Bénite France Recruiting
Chu de Reims - Hopital Robert Debre Reims France Recruiting
Centre Henri Becquerel Rouen France Recruiting
Centre Rene Hugenin Saint-Cloud France Recruiting
CH de Saint Malo St-Malo France Recruiting
CHRU de Strasbourg Strasbourg France Recruiting
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O) Toulouse France Recruiting

More The Lymphoma Academic Research Organisation trials in France

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 Active, not recruiting
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older Active, not recruiting
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy Active, not recruiting
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation Active, not recruiting
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04220970 on ClinicalTrials.gov ↗ ← All trials in France